Resource Center
Explore Resource Types
We have housed the technical documents (SDS, COAs, Manuals and more) in a dedicated section.
Explore all All Resources
Filters
Select resource types
Select products & services
Select solutions (2)
Active Filters (2)
Clear All
145 - 153 of 153 Results
Sort by:
Best Match
Application Note
Measuring strong to weak binding interactions with AlphaLISA
In this application note, we demonstrate how AlphaLISA can be used to measure three very different types of biomolecular interactions with three very different binding affinities.
Literature - Publication Review
Current approaches to identify possible COVID-19 therapeutics
Current approaches to identify possible COVID-19 treatment strategies fall into one of three categories: Antivirals, antibodies, or protein-protein interaction inhibitors.
Application Note
Rapid no wash assays for characterizing a mouse TIGIT/PD-L1 bispecific antibody
In this application note, we demonstrate how AlphaLISA™ assay technology can be used for bispecific antibody detection.
Application Note
Immunogenicity assessment using the AlphaLISA technology
In this application note, we demonstrate that the AlphaLISA™ mix-and-read homogeneous assay permits the sensitive detection of anti-drug antibodies (ADA). Learn more.
Whitepaper
Exploring current and future approaches for targeting KRAS
Get the latest insights on KRAS and see how it has switched from being an undruggable to a druggable cancer target
Flyer
Bioanalytical methods for biosimilarity assessment
Working in partnership to develop and qualify assays in the support of the biosimilarity assessment data package.
Application Note
Avoiding biotin interference in AlphaLISA assays
This application note demonstrates the value of using AlphaLISA biotin-free kits to reduce the effects of biotin interference in sample and standard preparations.
Application Note
No-Wash IP1 assays are a powerful readout to characterize compounds modulating the FGFR signaling pathway in cancer drug research
This application note demonstrates that detecting the intracellular accumulation of IP1, mediated by FGFR-dependent activation of PLCγ1, can be a powerful alternative for characterizing compounds that modulate FGFR signaling in various cancer cell lines expressing FGFR1, FGFR2, and FGFR3.
Whitepaper
Targeted protein degradation: A novel therapeutic strategy for neurodegenerative diseases
In this white paper, get details about TPD that offers a novel strategy for neurodegenerative diseases by degrading disease-linked proteins, showing promise in preclinical studies.
Looking for technical documents?
Find the technical documents you need, ASAP, in our easy-to-search library.